As of 2025-07-08, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -4.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 130.77 mil USD. YMAB's TTM EBITDA according to its financial statements is -26.56 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 13.7x | 13.0x |
| Forward P/E multiples | 18.7x - 28.4x | 23.5x |
| Fair Price | (9.62) - (6.68) | (9.40) |
| Upside | -327.8% - -258.3% | -322.8% |
| Date | EV/EBITDA |
| 2025-07-03 | -5.06 |
| 2025-07-02 | -4.99 |
| 2025-07-01 | -5.25 |
| 2025-06-30 | -5.42 |
| 2025-06-27 | -5.74 |
| 2025-06-26 | -5.91 |
| 2025-06-25 | -6.10 |
| 2025-06-24 | -6.47 |
| 2025-06-23 | -5.78 |
| 2025-06-20 | -5.25 |
| 2025-06-18 | -5.62 |
| 2025-06-17 | -5.91 |
| 2025-06-16 | -6.15 |
| 2025-06-13 | -5.76 |
| 2025-06-12 | -5.62 |
| 2025-06-11 | -6.13 |
| 2025-06-10 | -6.44 |
| 2025-06-09 | -6.39 |
| 2025-06-06 | -6.71 |
| 2025-06-05 | -6.42 |
| 2025-06-04 | -6.18 |
| 2025-06-03 | -6.03 |
| 2025-06-02 | -5.81 |
| 2025-05-30 | -5.57 |
| 2025-05-29 | -5.83 |
| 2025-05-28 | -5.60 |
| 2025-05-27 | -5.25 |
| 2025-05-23 | -5.09 |
| 2025-05-22 | -4.77 |
| 2025-05-21 | -4.72 |
| 2025-05-20 | -4.94 |
| 2025-05-19 | -4.84 |
| 2025-05-16 | -4.72 |
| 2025-05-15 | -4.31 |
| 2025-05-14 | -3.93 |
| 2025-05-13 | -4.82 |
| 2025-05-12 | -4.67 |
| 2025-05-09 | -4.36 |
| 2025-05-08 | -4.62 |
| 2025-05-07 | -4.34 |
| 2025-05-06 | -4.31 |
| 2025-05-05 | -4.97 |
| 2025-05-02 | -5.25 |
| 2025-05-01 | -4.74 |
| 2025-04-30 | -4.97 |
| 2025-04-29 | -4.89 |
| 2025-04-28 | -4.94 |
| 2025-04-25 | -4.72 |
| 2025-04-24 | -4.77 |
| 2025-04-23 | -4.75 |